We are live on
!
Find out more
KFO
Kopp Family Office Portfolio holdings
AUM
$163M
1-Year Est. Return
22.57%
This Fund
S&P 500
This Quarter
Est. Return
-8.8%
1 Year Est. Return
+22.57%
3 Year Est. Return
+33.98%
5 Year Est. Return
+1.93%
10 Year Est. Return
–
AUM
$146M
AUM Growth
-$11.7M
(-7.4%)
Cap. Flow
+$4.83M
Cap. Flow
% of AUM
3.31%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
3
Reduced
2
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vericel Corp
VCEL
|
+$9.72M |
| 2 |
FIVE9
FIVN
|
+$745K |
| 3 |
XENT
Intersect ENT, Inc
XENT
|
+$280K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NeoGenomics
NEO
|
+$5.57M |
| 2 |
SRGA
Surgalign Holdings, Inc. Common Stock
SRGA
|
+$356K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.24% |
| 2 | Technology | 2.05% |
Similar funds
OFM
PCR
TCGDR
IPWA
IVGAI
CC
GP
PWAM
Kopp Family Office's Q1 2020 Portfolio in Review
As of Q1 2020, Kopp Family Office held 5 positions worth $146M, down 7.4% from $157M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Kopp Family Office deployed $4.83M of net new capital in Q1 2020, adding to 3 existing holdings.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Technology.
On the sell side, the largest reduction was NeoGenomics, an estimated $5.57M trimmed.
- Kopp Family Office added most to Vericel Corp in Q1 2020, an estimated $9.72M increase.
- Kopp Family Office's biggest Q1 2020 reduction was NeoGenomics, cutting an estimated $5.57M.
- Kopp Family Office's ten largest holdings make up 100% of its $146M portfolio in Q1 2020.
- Kopp Family Office opened 0 new positions and closed 0 in Q1 2020.
- Kopp Family Office's portfolio value fell 7.4% quarter-over-quarter to $146M.
Based on Kopp Family Office's 13F filing for Q1 2020, filed 15 May 2020.